Cytokinetics gets bump after DMC says CVOT should proceed

Cytokinetics added $1.63 (19%) to $10.19 on Wednesday after it said a DMC recommended the Phase III GALACTIC-HF cardiovascular outcomes trial

Read the full 210 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE